White House Pulls Heidi Overton FDA Nomination Hours Before Senate Vote

The White House has withdrawn Dr Heidi Overton’s nomination to lead the Food and Drug Administration, pulling the Heidi Overton FDA nomination late on Tuesday 17 November 2026, hours before the Senate committee was due to vote on whether to advance it. The move, first reported by Axios and confirmed by a White House official, leaves the agency without a permanent commissioner and hands the Trump administration a fresh search for a leader of one of America’s most powerful health regulators.
Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated in August to replace Dr Marty Makary, who resigned as commissioner in May. Her bid collapsed after weeks of doubt among Senate Republicans, with the White House concluding she did not have the votes to clear the Senate Health, Education, Labor and Pensions (HELP) Committee.
Heidi Overton FDA Nomination — Quick Reference
| Fact | Detail |
|---|---|
| Nominee | Dr Heidi Overton, deputy director, White House Domestic Policy Council |
| Position | Commissioner, US Food and Drug Administration (FDA) |
| Withdrawn | Tuesday 17 November 2026, late evening |
| First reported by | Axios; confirmed by a White House official |
| Committee vote due | Wednesday 18 November 2026, Senate HELP Committee |
| Nominated | 19 August 2026 |
| Predecessor | Dr Marty Makary, resigned May 2026 |
| Acting commissioner | Kyle Diamantas, FDA Deputy Commissioner for Food |
| Reported replacement under consideration | Senator Roger Marshall of Kansas |
| Agency without a permanent leader since | May 2026 |
A Nomination Withdrawn on the Eve of the Vote
The timing was abrupt. The HELP Committee had been scheduled to vote at 10 a.m. on Wednesday 18 November on whether to send Overton’s nomination to the full Senate. Instead, the White House acted the night before, after concluding that support on the committee had slipped beyond repair. A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation”.
The committee’s chair, Senator Bill Cassidy of Louisiana, a physician, publicly disagreed with the decision within hours. “Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Cassidy wrote on X, maintaining that she had been on the verge of gathering enough support. The White House did not immediately respond to his claim.
The Senate Maths That Sank the Nomination
The arithmetic explains the withdrawal. The 21-member HELP Committee holds a one-vote Republican majority, and with Democrats expected to oppose the nomination, Overton needed the backing of every Republican on the panel. A single defection would have stopped her advancing.
That unanimity never arrived. Senators Susan Collins of Maine and Lisa Murkowski of Alaska had not said how they would vote in the hours before the withdrawal, according to CBS News. Other Republicans had raised concerns in private for weeks, and the White House chose to pull the nomination rather than risk a public defeat in committee.
The move is now likely to leave the FDA without a permanent leader well into next year, according to CNN. It also narrows the window for Republicans, with Democrats due to take control of the Senate in January, according to Medical Economics.
Vaccines, Abortion and Vapes: The Flashpoints
Overton’s confirmation hearing in September exposed the fault lines that followed her for the rest of the process. Senators pressed her on whether she would break from President Donald Trump on vaccine policy, after she backed his plan to break up the combination measles, mumps and rubella (MMR) vaccine into three separate jabs. She also helped draft and edit the scientific case for cutting the number of federally recommended childhood vaccinations from 18 to 11, a change that fed into the president’s executive order on childhood vaccinations.
Her stance on the abortion pill mifepristone drew fire from both directions. Democrats criticised her openly anti-abortion position and her criticism of the loosening of mifepristone dispensing rules under the Biden administration. At the same time, some conservatives questioned whether she would defend restrictions firmly enough.
Vaping added a third front. The administration authorised fruit-flavoured vaping products this year, and Calley Means, a health adviser who left the administration in October, accused Overton of working to relax the standards on flavoured vapes. The episode fed a wider argument inside the administration about whether its health policy was serving corporate interests or the “Make America Healthy Again” agenda.
The withdrawal fits a pattern. The White House has also pulled nominees to lead the Centers for Disease Control and Prevention and the surgeon general’s office after moderate Republicans raised concerns, CNN reported. The measles picture sharpens the stakes: the United States has just lost its measles elimination status after 26 years, with more than 5,400 cases recorded in 2026.
The MAHA Fault Line Inside the Administration
Behind the Senate maths sits a deeper split. Health and Human Services Secretary Robert F. Kennedy Jr. leads the “Make America Healthy Again” movement, and reporting by CNN described Overton’s relationship with Kennedy as “icy”. As the White House domestic policy aide handling health, Overton spent the past year and a half as the main link between Kennedy’s department and senior White House officials, a role that put her at the centre of disputes over which MAHA policies advanced and which stalled.
“She’s not MAHA,” one person familiar with the dynamic told CNN. Supporters of the movement argued that the administration withdrew her nomination rather than make commitments on policy that Kennedy’s allies had demanded. The dispute leaves open whether the next nominee will come from inside the MAHA movement or from the more traditional conservative circles that backed Overton.
What Happens to the FDA Now
Kyle Diamantas, an attorney who previously ran the agency’s food centre, continues to lead the FDA on an acting basis, a role he has held since Makary’s departure in May. The agency regulates prescription drugs, vaccines, medical devices and food safety, and it faces consequential decisions in the months ahead, including a safety review of mifepristone. Its recent decisions include ordering makers of GLP-1 drugs to add eye-risk warnings, as covered in our report on the Ozempic blindness warning.
Attention now turns to who Trump picks next. Reuters reported that the White House is weighing Senator Roger Marshall of Kansas, a former obstetrician who lost his re-election bid this month, as a replacement nominee. Marshall has expressed interest in the role, according to people familiar with private discussions. No decision has been announced, and the White House has given no timeline for a new nomination.
The FDA’s last permanent commissioner left in May, and the agency has now spent six months under acting leadership. The search for a successor starts again, with the same Senate arithmetic waiting for whoever is chosen next.
Frequently Asked Questions
Why was Heidi Overton’s FDA nomination withdrawn?
The White House concluded she did not have the votes to clear the Senate HELP Committee. With Democrats expected to oppose her, she needed every Republican on the 21-member panel, and that support was not there. The nomination was pulled late on Tuesday 17 November, the night before the scheduled vote.
Who is Heidi Overton?
Overton is a physician and deputy director of the White House Domestic Policy Council. She earned her medical degree from the University of New Mexico, trained in general surgery at Johns Hopkins, and holds a PhD in clinical investigation from the Johns Hopkins Bloomberg School of Public Health. She was a White House fellow in 2019–2020 and chief policy officer at the America First Policy Institute before rejoining the administration.
Who leads the FDA now?
Kyle Diamantas, the FDA’s Deputy Commissioner for Food, continues as acting commissioner, a post he has held since Dr Marty Makary resigned in May 2026.
Who could replace Overton as the nominee?
Senator Roger Marshall of Kansas is reported to be under consideration. The outgoing senator, a former obstetrician, has expressed interest in the role, but the White House has not announced a decision or a timeline.
What does the withdrawal mean for the FDA?
The agency is likely to remain without a permanent leader well into next year. It continues to operate under acting leadership while the White House searches for a new nominee who can win Senate confirmation.
Myth-busting: Overton was not rejected by the Senate. No vote on her nomination ever took place. The White House withdrew the nomination itself, before the HELP Committee could vote, after concluding the support was not there. That distinction matters: a withdrawal leaves the door open for a future nomination, while a committee defeat would have been a public rejection.



